Shubham Pant, MD, MD Anderson Cancer Center

Articles by Shubham Pant, MD, MD Anderson Cancer Center

Future of NTRK Fusions

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Challenges for TRK Fusion–Targeting Agents

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Acquired Resistance in TRK Fusion-Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Approaching Treatment for TRK Fusion–Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

TRK Inhibitor in GI Cancers: Adverse Effect Profile

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Efficacy of TRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Early Development of TRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Advice for Interpreting NGS Reports

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Driver Mutations in NTRK Fusion-Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Genomic Testing for NTRK Fusions in Lung and GI Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Approaching Genomic Testing for NTRK Fusions

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Using Molecular Testing in GI Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Evolution of NGS Testing in Lung Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Variants of NTRK Fusions in Solid Tumors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Role of NTRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

Latest Updated Articles

Driver Mutations in NTRK Fusion-Positive Cancers
May 21st 2020
Approaching Genomic Testing for NTRK Fusions
May 21st 2020
Role of NTRK Inhibitors
May 21st 2020
Challenges for TRK Fusion–Targeting Agents
May 21st 2020
Using Molecular Testing in GI Cancers
May 21st 2020
Variants of NTRK Fusions in Solid Tumors
May 21st 2020

Shubham Pant, MD, MD Anderson Cancer Center

Articles by Shubham Pant, MD, MD Anderson Cancer Center

Future of NTRK Fusions

Challenges for TRK Fusion–Targeting Agents

Acquired Resistance in TRK Fusion-Positive Cancers

Approaching Treatment for TRK Fusion–Positive Cancers

TRK Inhibitor in GI Cancers: Adverse Effect Profile

Efficacy of TRK Inhibitors

Early Development of TRK Inhibitors

Advice for Interpreting NGS Reports

Driver Mutations in NTRK Fusion-Positive Cancers

Genomic Testing for NTRK Fusions in Lung and GI Cancers

Approaching Genomic Testing for NTRK Fusions

Using Molecular Testing in GI Cancers

Evolution of NGS Testing in Lung Cancers

Variants of NTRK Fusions in Solid Tumors

Role of NTRK Inhibitors

Latest Updated Articles

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL

Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL